相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca et al.
BLOOD ADVANCES (2022)
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
Erica Brivio et al.
BLOOD (2021)
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes
Noa G. Holtzman et al.
NEURO-ONCOLOGY (2021)
Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
Carlota Gudiol et al.
LANCET HAEMATOLOGY (2021)
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Livio Pagano et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study
Giovanni Martinelli et al.
EUROPEAN JOURNAL OF CANCER (2021)
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Patrick A. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner et al.
BLOOD CANCER JOURNAL (2021)
Acute Lymphoblastic Leukemia, Version 2.2021
Patrick A. Brown et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis
Ghady Haider et al.
CLINICAL INFECTIOUS DISEASES (2020)
Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections
Russell E. Lewis et al.
CLINICAL INFECTIOUS DISEASES (2020)
Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections Reply
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2020)
Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults
Surabhi B. Vora et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy
Wei Liu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
Daniel J. DeAngelo et al.
BLOOD CANCER JOURNAL (2020)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Robin Foa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia
Alessandro Rambaldi et al.
BLOOD ADVANCES (2020)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Anthony S. Stein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection
Paolo Strati et al.
BLOOD (2019)
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Ankit J. Kansagra et al.
BONE MARROW TRANSPLANTATION (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)
Roberta Di Blasi et al.
ANNALS OF HEMATOLOGY (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
Jae H. Park et al.
CLINICAL INFECTIOUS DISEASES (2018)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage
Elias Jabbour et al.
CANCER (2018)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Joshua A. Hill et al.
BLOOD (2018)
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Gunilla Enblad et al.
CLINICAL CANCER RESEARCH (2018)
Infection-related complications during treatment for childhood acute lymphoblastic leukemia
H. Inaba et al.
ANNALS OF ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Infectious complications in children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group protocol: A 16-year tertiary single-institution experience
Meng-Ju Li et al.
PEDIATRIC BLOOD & CANCER (2017)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Hoelzer et al.
ANNALS OF ONCOLOGY (2016)
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Sebastien Maury et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003
David O'Connor et al.
BLOOD (2014)
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Dieter Hoelzer et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dose-Intensive Chemotherapy Including Rituximab in Burkitt's Leukemia or Lymphoma Regardless of Human Immunodeficiency Virus Infection Status Final Results of a Phase 2 Study (Burkimab)
Josep-Maria Ribera et al.
CANCER (2013)
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program
Tamara Intermesoli et al.
HAEMATOLOGICA (2013)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy
Oliver A. Cornely et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Revised definition of 'fever of unknown origin': limitations and opportunities
O Ergonul et al.
JOURNAL OF INFECTION (2005)
分享论文
